Private equity firms including Bain Capital and Kolberg notably invested in PCI Pharma Services, valuing the company at $10 billion. The contract development and manufacturing organization supports biopharma clients in drug manufacturing and packaging, including major launches such as Novo Nordisk’s Wegovy. The fresh capital will fuel geographic expansion, capacity increases for specialized medicines, including PROTACs and antibody-drug conjugates, and investments in U.S. facilities, underscoring strong confidence in CDMO sector growth.